CybernaX Announces Comprehensive Licensing Agreement with Merck for Proprietary Lipid Library

2024Year7Day 24 — Nanjing Xingchen Zhiyao Biomedical Technology Co., Ltd. (CybernaX) announced that it has reached a comprehensive licensing and cooperation agreement with Merck KGaA, a leading technology company headquartered in Darmstadt, Germany (hereinafter referred to as "Merck"), for its self-developed high-efficiency lipid library.

The core of this collaboration revolves around the proprietary nucleic acid lipid delivery technology of Nanjing Xingchen Zhiyao Biomedical Technology Co., Ltd.The lipids of Nanjing Xingchen Zhiyao Biomedical Technology Co., Ltd. are highly efficientmRNAEncapsulation and delivery efficiency, good safety, and the ability to selectively deliver to specific non-liver targets are crucial for the development of nucleic acid drugs and their application in new therapeutic fields.

Nanjing Xingchen Zhiyao Biomedical Technology Co., Ltd. management team stated:“The collaboration with Merck marks our advancementCybernaXAn important step in the global commercialization strategy of the proprietary lipid library. We are delighted to collaborate with a leading multinational company. The rich and innovative lipid library of Nanjing Xingchen Zhiyao Biomedical Technology Co., Ltd. will have the opportunity to assist in the screening, validation, and potential commercialization process of nucleic acid drugs worldwide.”

Executive Director of Merck KGaA Germany,mRNAHead of Targeted DeliveryKahina LangDr. stated: "This collaboration will strengthen Merck's position in lipid nanoparticle-basedmRNALeading Advantages in the Field of Targeted Delivery Solutions. Through collaboration withCybernaXThrough cooperation, we will be able to further push the technological boundaries in the field of next-generation lipid nanoparticles and nucleic acid drugs, thereby providing better services to our customers.mRNADifferentiated and integrated services and solutions on the value chain.”

About CybernaX

Nanjing Xingchen Zhiyao Biomedical Technology Co., Ltd. is a biotechnology company focused on developing novel lipid delivery systems for nucleic acid drugs.With a proprietary vast lipid library, we are accelerating the application of lipid delivery tools in fields such as vaccines, oncology, rare diseases, gene editing, early detection, and novel drug delivery routes (inhalation).We are committed to providing breakthrough nucleic acid therapies for unmet global medical needs, making nucleic acid delivery accessible.For more information about the technology platforms and collaborations of Nanjing Xingchen Zhiyao Biomedical Technology Co., Ltd., please contact us viainfo@cybernaxbio.comContact Us.